Tempus AI (NASDAQ:TEM) EVP Sells $422,486.08 in Stock

Tempus AI logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Tempus AI EVP Andrew Polovin sold 6,704 shares for $422,486 at an average price of $63.02. The sale covered tax withholding on vested equity awards; he retained 128,485 shares.
  • Tempus AI reported quarterly EPS of $0.07, beating the consensus estimate of a $0.09 loss, while revenue of $411.54 million rose 23.1% year over year.
  • Analysts’ consensus rating is Hold, with an average price target of $79.37; shares recently traded at $59.61.
  • MarketBeat previews the top five stocks to own by December 1st.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) EVP Andrew Polovin sold 6,704 shares of Tempus AI stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total transaction of $422,486.08. Following the completion of the sale, the executive vice president directly owned 128,485 shares in the company, valued at approximately $8,097,124.70. This represents a 4.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

  • On Thursday, September 17th, Andrew Polovin sold 2,951 shares of Tempus AI stock. The shares were sold at an average price of $75.00, for a total transaction of $221,325.00.

Tempus AI Stock Performance

Shares of Tempus AI stock traded down $4.01 on Thursday, reaching $59.61. 5,290,938 shares of the company traded hands, compared to its average volume of 6,229,094. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $89.09. The company has a 50 day moving average of $72.87 and a 200 day moving average of $57.56. The firm has a market capitalization of $10.87 billion, a PE ratio of -56.24 and a beta of 3.61. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 2.48.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.16. The company had revenue of $411.54 million during the quarter, compared to analyst estimates of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. Tempus AI's quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.46) EPS. Equities analysts forecast that Tempus AI, Inc. will post -1.20 earnings per share for the current year.

Hedge Funds Weigh In On Tempus AI

A number of large investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. purchased a new position in shares of Tempus AI in the third quarter valued at $3,977,000. Integrated Wealth Concepts LLC lifted its holdings in Tempus AI by 44.3% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 3,618 shares of the company's stock worth $296,000 after purchasing an additional 1,110 shares in the last quarter. Schwarz Investment Partners Inc. bought a new position in Tempus AI in the 3rd quarter worth about $109,000. New York State Common Retirement Fund boosted its stake in Tempus AI by 3.0% in the 3rd quarter. New York State Common Retirement Fund now owns 54,400 shares of the company's stock worth $4,455,000 after purchasing an additional 1,600 shares during the period. Finally, Allworth Financial LP lifted its stake in Tempus AI by 203.7% in the 3rd quarter. Allworth Financial LP now owns 2,542 shares of the company's stock worth $208,000 after purchasing an additional 1,705 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI News Roundup

Here's some of the latest news about TEM:

  • Positive Sentiment: Tempus will present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium. The research exposure could showcase its oncology data and precision-medicine capabilities, though the headline does not disclose results or commercial impact. Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
  • Positive Sentiment: Tempus and AstraZeneca extended their strategic services agreement through a fifth amendment. The expanded relationship may support Tempus’s data and services business and validates its capabilities with a major pharmaceutical partner; the supplied summaries do not specify the financial terms. Tempus AI and AstraZeneca Extend Strategic Services Agreement
  • Positive Sentiment: A recent investor-focused article cites data agreements expected to generate $193 million over five years and oncology pricing changes expected to add $80 million in average selling price during 2027. These figures offer potential revenue support, although they depend on execution and timing. Tempus AI: 3 Key Takeaways for Long-Term Investors

Wall Street Analyst Weigh In

Several analysts have issued reports on TEM shares. BTIG Research boosted their target price on Tempus AI from $80.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, November 3rd. UBS Group began coverage on Tempus AI in a research note on Wednesday, September 9th. They set a "neutral" rating and a $70.00 price target for the company. Guggenheim lifted their price objective on Tempus AI from $65.00 to $92.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Canaccord Genuity Group boosted their price objective on Tempus AI from $80.00 to $95.00 and gave the company a "buy" rating in a research note on Monday, October 12th. Finally, Piper Sandler raised shares of Tempus AI from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $56.00 to $76.00 in a report on Tuesday, September 1st. Eleven equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Tempus AI presently has an average rating of "Hold" and a consensus target price of $79.37.

Check Out Our Latest Analysis on TEM

Tempus AI Company Profile

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Recommended Stories

Insider Buying and Selling by Quarter for Tempus AI (NASDAQ:TEM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tempus AI Right Now?

Before you consider Tempus AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.

While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines